Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Study of dronabinol and cannabidiol oral solution for symptom relief in advanced cancer patients receiving opioid treatment

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on managing symptoms in patients with advanced cancer who are receiving strong pain medications called opioids. The research examines how a combination of two cannabis-derived substances - dronabinol and cannabidiol (Cannabis Extract Avextra 10/10 Solution) - might help reduce various symptoms that cancer patients experience, such as pain, nausea, loss of appetite, and fatigue.

The purpose of this research is to evaluate if adding this cannabis extract solution to current pain treatment can improve overall symptom management compared to placebo. The medication being tested is taken by mouth as a liquid solution. Study participants will receive either the cannabis extract or placebo while continuing their regular pain medications.

The study will last 8 weeks, during which participants will be monitored for changes in their symptoms. The research team will assess various aspects of well-being, including sleep quality, appetite, energy levels, and pain intensity. This will help determine how effective the cannabis extract is at relieving multiple symptoms that cancer patients commonly experience.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment and medication start

    You will receive either Cannabis Extract Avextra 10/10 Solution or a placebo (inactive substance that looks the same)

    The solution is taken by mouth

    You will continue your current pain medications (opioids) and other treatments during the study

  2. Step 2

    Treatment period

    The treatment continues for 8 weeks

    You will take the oral solution while maintaining your regular cancer treatment

    Your symptoms will be monitored using various assessment tools:

    - ESAS questionnaire to measure overall symptom burden

    - Assessment of nutrition status

    - Evaluation of sleep quality

    - Assessment of nerve pain

    - Measurement of fatigue levels

  3. Step 3

    Storage requirements

    Keep the medication in a tightly closed container

    Store at temperature below 25°C

    Protect from light

  4. Step 4

    Final assessment

    After 8 weeks, your symptoms will be evaluated again using the same questionnaires

    The effectiveness of the treatment will be measured by comparing your symptom scores to the initial assessment

  5. Step 5

    Safety requirements

    If you are able to become pregnant, you must:

    - Have a negative pregnancy test before starting

    - Use two effective methods of birth control during the study

Who can join the trial?

12 criteria

  • Must provide written informed consent to participate in the study
  • Must be 18 years or older, any sex, gender, sexual orientation, and ethnicity
  • Must not have used cannabis in the past 6 months
  • Must have advanced cancer with a life expectancy of at least 6 months
  • Must be currently receiving active cancer treatment
  • Must have at least one of these symptoms:
    • Physical symptoms like moderate to severe pain, nausea, vomiting, poor appetite, or fatigue
    • Mental health symptoms like anxiety, depression, or difficulty sleeping
    • Must have a performance status (ability to perform daily activities) score of 3 or better
    • Must have a total symptom distress score of 16 or higher on the Edmonton Symptom Assessment System (a tool that measures different symptoms)
    • Must be taking stable doses of strong or moderate pain medications and/or other supportive medications
    • For women who can become pregnant:
      • Must have a negative pregnancy test
      • Must use two highly effective methods of birth control (with less than 1% chance of pregnancy)

Who cannot join the trial?

14 criteria

  • Known allergy or hypersensitivity to cannabis, THC, CBD, or any components of the study medication
  • History of severe psychiatric disorders (such as schizophrenia, severe depression, or severe anxiety disorders)
  • Significant heart conditions including unstable heart disease or recent heart attack
  • Liver dysfunction (serious problems with liver function)
  • Current or past substance use disorder including cannabis use disorder
  • Pregnant women or women who are breastfeeding
  • Using medications that could interact with cannabis-based products
  • Unable to provide informed consent
  • Participation in another clinical trial within the past 30 days
  • Unstable medical condition that could interfere with study participation
  • History of seizures or epilepsy
  • Severe kidney disease (problems with kidney function)
  • Unable to follow study procedures or attend scheduled visits
  • Current use of any form of cannabis or cannabis-derived products
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Cannabis extract Avextra 10/10

    is an oral solution containing balanced amounts of THC (tetrahydrocannabinol) and CBD (cannabidiol). It is derived from the cannabis plant and is being studied as an additional treatment for managing symptoms in cancer patients. This medication is designed to help reduce the overall symptom burden in patients who are already receiving strong pain medications (opioids) as part of their cancer treatment.

  • WHO level II and III opioids

    are strong pain medications commonly used to manage moderate to severe pain in cancer patients. These medications are part of the standard treatment that patients receive for pain management during their cancer care.

What is already known about the treatment

Cannabis extract Avextra 10/10 - An oral solution containing balanced amounts of THC (tetrahydrocannabinol) and CBD (cannabidiol), designed for therapeutic use in advanced cancer patients. This investigational medication is administered orally and is being studied as an add-on therapy for patients already receiving WHO level II or III opioids for cancer-related symptoms. The extract works through interaction with the endocannabinoid system, potentially helping to manage multiple symptoms commonly experienced by cancer patients, including pain, nausea, and distress. As a balanced THC/CBD formulation, it represents a standardized approach to medical cannabis administration in clinical settings, with the goal of providing symptom relief while maintaining a controlled ratio of active compounds.

Investigated diseases

  • Advanced Cancer

    A condition where cancer cells have spread beyond their original location to other parts of the body. The disease affects normal body functions and can cause various symptoms including pain, fatigue, and changes in appetite. As cancer progresses, it can impact multiple organ systems and lead to various physical complications. The condition often causes changes in the patient's daily activities and quality of life. Patients may experience different symptoms depending on the type and location of cancer.

  • Chronic Cancer Pain

    A persistent pain condition that occurs in cancer patients due to tumor growth, nerve compression, or other cancer-related factors. The pain can be constant or intermittent, varying in intensity throughout the day. Cancer pain can affect different parts of the body and may change in character over time. The condition can significantly impact sleep patterns and daily activities.

  • Cancer-related Sleep Disorders

    A group of sleep disturbances that commonly occur in cancer patients, characterized by difficulty falling asleep, staying asleep, or getting restful sleep. These sleep problems can occur at any stage of cancer and may fluctuate in severity. The condition often accompanies other cancer-related symptoms and can affect daytime functioning.

  • Cancer-related Fatigue

    A persistent feeling of physical, emotional, and mental tiredness related to cancer that is not relieved by rest. This fatigue differs from normal tiredness and can occur even after minimal activity. The condition can affect daily activities and social interactions. The intensity of fatigue may vary throughout the day and during different stages of cancer.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-519568-42-00Protocol codeCAPTUREEstimated enrolment156 patientsSponsorIRCCS Istituto Nazionale Tumori Fondazione Pascale

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).